German Hypoparathyroidism Registry

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational, local registry that documents medical history and follow-up data for adults with chronic hypoparathyroidism or pseudohypoparathyroidism in Germany. It collects information about disease manifestations, treatments, and outcomes to improve understanding of the condition beyond standard calcium and vitamin D therapy. The registry aims to support clinical, translational, and basic research by providing structured, longitudinal data. Participation requires informed consent and residency in Germany, with a focus on patients and a comparison group of post-thyroidectomy patients on thyroid hormone replacement. Lead coordination is at University Hospital Augsburg with collaboration from Würzburg University Hospital and Ascendis Pharma Endocrinology.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* diagnosis of chronic hypo- or pseudohypoparathyroidism \> 6 months or diagnosis of pseudohypoparathyroidism
* age \>= 18 yrs.
* residing in Germany
* Written consent for patients capable of giving informed consent

Exclusion Criteria:

* Minors and patients with severe mental illnesses, or patients who are unable to provide written informed consent.

Controll group

* h/o thyroidektomy with thyroid hormone replacement
* age \>= 18 yrs.
* residing in Germany
* The exclusion criteria also apply to this group.

Where it's running

• University Hospital Augsburg
  Augsburg, Bavaria, Germany Recruiting

Study contacts

• Study coordinator: Christina M. Berr, Dr.
• Email: endokrinologie@uk-augsburg.de
• Phone: +498214003938

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Encaleret for Chronic Hypoparathyroidism: Testing if it helps symptoms and safety

  This study tests whether taking encaleret pills can help people with chronic hypoparathyroidism, while being safe and tolerable.

  Recruiting at 5 sites Phase 3 Calcilytix Therapeutics, Inc., a BridgeBio company · Reno, Nevada and 4 other locations · NCT07805356

• Palopegteriparatide in adolescents with long-term hypoparathyroidism

  This study tests whether a once-daily palopegteriparatide shot helps adolescents with long‑standing hypoparathyroidism and whether it’s safe for them.

  Recruiting at 3 sites Phase 3 Ascendis Pharma A/S · Bron and 2 other locations · NCT07706764

• Canvuparatide vs placebo in adults with hypoparathyroidism

  This study tests whether weekly canvuparatide can help adults with hypoparathyroidism feel better and keep calcium levels steady compared with a placebo.

  Recruiting at 22 sites Phase 3 MBX Biosciences · Englewood, Colorado and 21 other locations · NCT07699471

• NIRAF-guided identification of parathyroids during thyroidectomy

  A wearable near-infrared autofluorescence device is being tested to help surgeons find and protect the parathyroid glands during thyroid surgery in adults.

  Recruiting Ss. Cyril and Methodius University of Skopje · Skopje · NCT07617584

• Pregnancy registry tracking outcomes after YORVIPATH exposure during pregnancy and breastfeeding

  This registry collects information from pregnant or breastfeeding people with hypoparathyroidism who took YORVIPATH to see if the exposure affects pregnancy, the baby, or infant outcomes through the first year of life.

  Recruiting Ascendis Pharma A/S · Morgantown, West Virginia · NCT07345494

• Palopegteriparatide levels in breast milk of lactating individuals taking YORVIPATH.

  This will see if palopegteriparatide (YORVIPATH) appears in the breast milk of lactating adults with hypoparathyroidism who are breastfeeding.

  Recruiting Ascendis Pharma A/S · Morgantown, West Virginia · NCT07264634

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.